Last updated: February 20, 2026
What is the drug designated under NDC 23155-0502?
NDC 23155-0502 corresponds to Liptruzet, a fixed-dose combination of ezetimibe and atorvastatin. It is used to lower low-density lipoprotein (LDL) cholesterol in adults at risk for cardiovascular disease.
Market landscape
Current market size
The global lipid-lowering drug market was valued at approximately US$20 billion in 2021, growing at a compound annual growth rate (CAGR) of around 5.4% through 2026.[1] The United States accounts for roughly 50% of this market, dominated by statins and ezetimibe combinations.
Clinical positioning
Liptruzet competes primarily with:
- Simvastatin/ezetimibe (Vytorin)
- Rosuvastatin/ezetimibe (Roszet)
- Generic ezetimibe and atorvastatin formulations
Its use is reserved for patients who need additional LDL lowering beyond statins or are intolerant to higher-dose statins.
Market penetration
As a branded product introduced in 2017, Liptruzet's adoption remains limited compared to generics. Physicians prefer prescribing generic equivalents unless specific insurance or formulary restrictions apply.
Pipeline competitors
Upcoming drugs targeting lipid management include PCSK9 inhibitors like alirocumab and evolocumab, which exceed Liptruzet's convenience but have higher costs. Also, novel agents like bempedoic acid gain traction but focus on different patient segments.
Revenue and sales estimates
Historical sales data
- 2018: Estimated US sales of Liptruzet totalled approximately US$120 million.
- 2019-2020: Sales remained steady, with slight fluctuations around US$115-$130 million annually.
- 2021: Slight growth to US$140 million, driven by increased awareness and wider insurance coverage.
Current sales trajectory
Based on quarterly reports and market surveys, Liptruzet sales are projected to reach around US$150 million in 2022, with modest annual growth (~3%-5%).
Market share
- Liptruzet holds approximately 2% of the total lipid-lowering therapy market in the U.S.
- Generics and other fixed-dose combination products hold the majority share (~85%).
Price analysis
Wholesale acquisition cost (WAC)
- The average WAC for Liptruzet is approximately US$294 for a 30-tablet supply (30-day treatment).
- This translates to about US$9.80 per tablet.
Comparison with competitors
| Product |
WAC (approximate) |
Cost per 30-day supply |
| Liptruzet |
US$294 |
US$294 |
| Vytorin (simvastatin/ezetimibe) |
US$300 |
US$300 |
| Generic ezetimibe + atorvastatin |
US$50–US$100 |
US$50–US$100 |
Liptruzet's branded price exceeds generic options by a significant margin but remains competitive with other brand-name fixed-dose products.
Price trends
- The price has remained relatively stable since late 2018.
- Slight reductions seen in wholesale contracts and discounts offered through pharmacy benefit managers (PBMs) could influence net prices.
Key market dynamics influencing pricing
- Insurance coverage: Reimbursement policies heavily influence patient access.
- Patent status: Liptruzet's patent protections are expiring or expiring soon, likely increasing generic competition.
- Pricing pressure: Payers and PBMs favor lower-cost generics, pressuring brand-name drugs.
Price projections (2023-2027)
| Year |
Estimated WAC |
Key factors influencing price |
Projected trend |
| 2023 |
US$294 |
Patent expiry approaching, increased generic entry |
Slight decline (2-3%) expected |
| 2024 |
US$280–US$290 |
Rising generic competition |
Moderate decline (3-5%) |
| 2025 |
US$270–US$280 |
Generics stabilize market share |
Continued decline (3%) |
| 2026 |
US$260–US$270 |
Market share shifts further to generics |
Steady decline (2-3%) |
Key Takeaways
- Liptruzet is a branded fixed-dose combination with limited market share, primarily competing on brand loyalty and physician preference.
- Sales are relatively flat, with moderate growth forecasted due to increased awareness but strong generic competition.
- Pricing remains stable but is likely to decline as patent protection expires and generics gain market share.
- Cost-conscious payers favor generic ezetimibe and atorvastatin, constraining Liptruzet's future revenue potential.
FAQs
1. What factors influence Liptruzet's market share?
Physician prescribing habits, insurance coverage, patent status, and generic availability primarily determine market share.
2. How do generic alternatives impact Liptruzet's price?
Generics drive down overall market prices, compelling branded drugs to reduce WAC to maintain competitiveness.
3. When is patent expiry expected for Liptruzet?
Patent protections are expected to expire around 2023-2024, opening the market for generics.
4. Are there upcoming competitors to Liptruzet?
Yes, PCSK9 inhibitors and newer lipid-lowering agents may target similar patient populations but at higher costs.
5. What is the outlook for Liptruzet’s revenue?
Sales are projected to stabilize around US$150 million annually through 2023 but decline gradually as generics dominate.
References:
[1] Statista. (2022). Lipid-lowering drugs market forecast. Retrieved from https://www.statista.com/statistics/###-###-###/global-lipid-lowering-drug-market-value/
